Navigation Links
Aprea to Present Phase I/II Trial Design
Date:5/18/2010

STOCKHOLM, May 18, 2010 /PRNewswire/ -- Among more than 5000 poster abstracts, Aprea AB has been selected to present a poster at the annual American Society of Clinical Oncology (ASCO) Meeting in Chicago. The presentation will describe the scientific rational and design of the ongoing phase I/II clinical trial with Aprea's drug candidate APR-246.

Aprea's drug candidate APR-246 belongs to a new class of anticancer compounds shown to induce programmed cell death through a p53 mediated mode of action. The compound is currently being tested in a phase I/II clinical trial at seven clinics in Sweden. The study will include approximately 24 patients, and is an open labeled, dose-escalating study on mainly blood cancer patients, but also patients with prostate cancer.

"We are currently initiating the commercialization process and seeking partners. Therefore, it will be very interesting to have the opportunity to present and discuss the clinical study design of this totally new concept of treating cancer", says Charlotta Liljebris, Head of Development at Aprea AB.

To the editors

About Aprea

Aprea AB is a Swedish biotech company founded in 2003 and based on research performed at the Karolinska Institutet, Stockholm, Sweden. The company focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea is a Karolinska Development AB (publ) portfolio compan
'/>"/>

SOURCE Karolinska Development and Aprea
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. Avicena Group to Present at Noble Financial Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CEL-SCI to Present at the Noble Financial Conference
7. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Strategic Diagnostics Updates Roth Conference Presentation Time
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Israel Biomedical Sensors Market - Growth, ... The Israel Biomedical Sensors market is ... of 3.73% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/31/2015)... 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapies primarily in the areas ... 30-day review period following the filing of the ... with the U.S. Food and Drug Administration (FDA) ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... 31, 2015 LabStyle Innovations Corp. (OTCQB: ... today announced it recently closed a round of ... used to support the global rollout and initial ... cloud-based, diabetes management solution that includes novel software ... glucose monitoring device, and for working capital purposes. ...
(Date:8/31/2015)... Redwood City, CA (PRWEB) , ... August 31, 2015 , ... ... Ablation System. Minerva is the first commercially available new FDA approved system ... high treatment Success rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... EntreMed, Inc.,(Nasdaq: ENMD ), a ... of cancer and inflammatory diseases, today,announced the ... or 2-,methoxyestradiol) in rheumatoid arthritis (RA). The ... Dr. Ernest Brahn, Professor of,Medicine, Rheumatology Program ...
... and LOD, Israel, November 3 Simbionix,USA Corporation ... for training medical professionals, today announced that William,E. ... Marketing Director on,November 10th, 2008. Gary Zamler, Simbionix ... has enjoyed double digit revenue growth in,both our ...
... elusive metal-hydroxide compound in sufficient and rapidly produced ... inks that could boost semiconductor capabilities for large-area ... of possibly the first heterometallic gallium-indium hydroxide nanocluster ... in place of nitrosobenzene. , The substitute was ...
Cached Biology Technology:Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models 2Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models 3Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models 4William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionix's Strategic Expansion in the US Market 2New nanocluster to boost thin films for semiconductors 2
(Date:8/5/2015)... 5, 2015 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... facial recognition is forecast to reach US$ 2,671.8 Mn ... for surveillance systems by civil and government agencies. This ... and terrorist activities across the globe that would elevate ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... would happen if a fast-food restaurant reduces the calories ... decreasing the portion size of French fries? Would children ... beverage? Researchers at Cornell University, Dr. Brian Wansink and ... McDonald,s restaurants to answer that question. Prior to ...
... predict sinkholes? What do ancient ambers reveal about paleochemotaxonomy? ... us understand current global warming? Did trilobites venture into ... above sea level? What does the 27 March 2013 ... you reconstruct snapshots of a catastrophic radial current? What ...
... The wild bison roaming Catalina Island are a major attraction ... Island,s most popular destination every year. But managing the number ... endanger the health of the rest of the Island has ... new study by the Catalina Island Conservancy scientists, published in ...
Cached Biology News:Healthier Happy Meals 2New geology research explores intriguing questions 2New geology research explores intriguing questions 3New geology research explores intriguing questions 4New geology research explores intriguing questions 5New geology research explores intriguing questions 6New geology research explores intriguing questions 7New geology research explores intriguing questions 8New geology research explores intriguing questions 9Study finds Catalina Island Conservancy contraception program effectively manages bison population 2
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: